Position statement of the American Association for geriatric psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease

American Journal of Geriatric Psychiatry

Volumn 14, Issue 7, 2006, Pages 561-573

  Lyketsos, Constantine G ^a   Colenda, Christopher C ^a   Beck, Cornelia ^a   Blank, Karen ^a   Doraiswamy, Murali P ^a   Kalunian, Douglas A ^a   Yaffe, Kristine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID PRECURSOR PROTEIN; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ASCORBIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; HUPERZINE A; IBUPROFEN; INDOMETACIN; MOOD STABILIZER; NONSTEROID ANTIINFLAMMATORY AGENT; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; TACRINE;

ALZHEIMER DISEASE; COGNITIVE DEFECT; COGNITIVE IMPAIRMENT NO DEMENTIA; COGNITIVE THERAPY; DEMENTIA; ELDERLY CARE; GERONTOPSYCHIATRY; HUMAN; PALLIATIVE THERAPY; REVIEW; SOCIALIZATION; VITAMIN INTAKE;

EID: 33745843336     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.JGP.0000221334.65330.55     Document Type: Article

References (45)

1. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition with Text Revision. Washington, DC, American Psychiatric Association, 2003
2. Hebert LE, Scherr PA, Bienias JL, et al: Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60:1119-1122
3. Black BS, Kasper J, Brandt J, et al: Identifying dementia in high-risk community samples: the memory and medical care study. Alzheimer Dis Assoc Disord 2003; 17:9-18
4. Barton C, Miller B, Yaffe K: Evaluation of the diagnosis and management of cognitive impairment in long-term care. Alzheimer Dis Assoc Disord 2003; 17:72-76
5. Rosenblatt A, Samus Q, Steele C, et al: The Maryland Assisted Living Study: prevalence, recognition and treatment of dementia and other psychiatric disorders in the assisted living population of central Maryland. J Am Geriatr Soc 2004; 52:1618-1625
6. Mulnard R, Cotman C, Kawas C, et al: Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a randomized, controlled trial. JAMA 2000; 283:1007-1015
7. Henderson V, Paganini-Hill A, Miller V, et al: Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000; 54:395-401
8. Zandi PP, Carlson MC, Plassman BL, et al: Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002; 288:2123-2129
9. Yip AG, Green RC, Huyck M: Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE study. BMC Geriatr 2005; 5:2
10. Aisen PS, Davis KL, Berg JD, et al: A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 2000; 54:588-593
11. Aisen PS, Schmeidler J, Pasinetti GM, et al: Randomized pilot study of numesulide treatment in Alzheimer's disease. Neurology 2002; 58:1050-1054
12. Aisen PS, Schafer K, Grundman M, et al: Effects of rofecoxib and naproxen vs. placebo on Alzheimer's disease progression. A randomized controlled trial. JAMA 2003; 289:2865-2867
13. Sainati SM, Ingram DN, Talwaker S, et al: Results of a double blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Stockholm, Sweden, 2000: 180
14. Van Gool WA, Weinstein HC, Scheltens PK, et al: Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomized, double-blind, placebo-controlled study. Lancet 2001; 358:455-460
15. Thal LJ, Ferris SH, Kirby L, et al: A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005; Mar 2 [Epub ahead of print]
16. Zandi PP, Anthony JC, Khachaturian AS, et al: Cache County Study Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004; 61:82-88
17. Sano M, Ernesto C, Thomas RG, et al: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336:1216-1222
18. Petersen RC, Thomas RG, Grundman M, et al: Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; April 13 [Epub ahead of print]
19. Miller 3rd, ER Pastor-Barriuso R, Dalal D, et al: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142:37-46. Epub 2004 Nov 10.
20. Summary for patients in: Ann Intern Med 2005; 142:140
21. van Dongen M, van Rossum E, Kessels A, et al: Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol 2003; 56:367-376
22. Snowdon DA, Greiner LH, Mortimer JA, et al: Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA 1997; 277:813-817
23. Adecola C, Gorelick PB: Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 2003; 34:335-337
24. Papademetriou V: Hypertension and cognitive function. Blood pressure regulation and cognitive function: a review of the literature. Geriatrics 2005; 60:20-22, 24
25. Jick H: Statins and the risk of dementia. Lancet 2000; 356:1627-1631
26. Shepherd J, Blauw G, Murphy M, et al: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360:1623-1630
27. Scarpini E, Scheltens P, Feldman H: Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2003; 2:539-547
28. Winblad B, Poritis N: Memantine in severe dementia: results of the M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14:135-146
29. Reisberg B, Doody R, Stoffer A, et al: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348:1333-1341
30. Tariot PN, Farlow MR, Grossberg GT, et al: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291:317-324
31. Plosker GL, Lyseng-Williamson KA: Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease. Pharmacoeconomics 2005; 23:193-206
32. Rabins PV, Lyketsos CG, Steele CD: Practical Dementia Care, 2nd Ed. Oxford, Oxford University Press, 2005
33. Lyketsos CG, Lee HB: Depression and treatment of depression in Alzheimer's disease: a practical update for the clinician. Dement Geriatr Cogn Disord 2004; 17:55-64
34. Kaufer DI, Cummings JL, Ketchel P, et al: Validation of the NP1-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000; 12:233-239
35. Livingston G, Johnston K, Katona C, et al: Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005; 162:1996-2021
36. Sink KM, Holden KF, Yaffe K: Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293:596-608
37. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934-1943
38. Wang PS, Schneeweiss S, Avorn J, et al: Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353:2335-2341
39. Murman DL, Colenda CC: The economic impact of neuropsychiatric symptoms in Alzheimer's disease: can drugs ease the burden? Pharmacoeconomics 2005; 23:227-242
40. Alexopoulos GS, Jeste DV, Chung H, et al: Treatment of dementia and its behavioral disturbances: consensus panel. Postgrad Med 2005
41. American Psychiatric Association: Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997; 154(suppl): 1-39
42. AAGP Atypical Position Statement. Available at: http://www. aagponline.org/prof/antipsychstat_0705.asp
43. Rabins PV, Lyketsos CG, Steele CD: Practical Dementia Care, 2nd Ed. Oxford, Oxford University Press, 2006
44. Dubinsky RM, Stein AC, Lyons K: Practice parameter: risk of driving and Alzheimer's Disease (an evidence based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54:2205-2211
45. Lyketsos CG, Toone L, Tschanz JT, et al: A population-based study of medical co-morbidity in early dementia and cognitive impairment no dementia (CIND): association with functional and cognitive impairment. The Cache County Study. Am J Geriatr Psychiatry 2005; 13:656-664